The chief executive of health watchdog Nice told ITV News he is "disappointed" that drug manufacturer Roche has not offered the NHS a discount on a breast cancer drug that costs around £90,000 per patient.
Kadcyla, which extends women's lives by almost six months, could be blocked from routine NHS access because it is too expensive.
"Companies can discount their prices and they frequently do. Given the list price. I would have expected the company to have at least considered (a discount)," Andrew Dillon said.
More top news
Thousands of people downstream of a dam have been evacuated, but authorities are unable to reach many on the hurricane-hit island.
Only half of the 4.2 million of eligible couples are applying for a marriage allowance that could be saving them hundreds each year.
Analysts said the outlook for the UK's public finances had "weakened significantly" with Brexit likely to put more pressure on the economy.